Firma Nomad Bioscience, Autor bei PR-Web

NOMAD BIOSCIENCE Extends and Broadens Its Agreements with Research and Commercial Growers, Spain, to Conduct Pilot Field and Greenhouse Trials Aimed at Industrial Manufacturing of Its Protein Products

Posted on 6. June 20236. June 2023 by Firma Nomad Bioscience Posted in General Tagged agri, clinical, ctaex, del, exploration, extremadura, ibmcp, market, nomads, olive, olivos, origin, tabacoex, thaumatin, with

NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has renewed and extended its development and production agreements with CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURA (“CTAEX”), Badajoz, TABACOEX cooperative, Rosalejo, and OLIVOS DE BADAJOZ, Badajoz in Extremadura region […]

Nomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend their Research and Development Agreement

Posted on 24. January 202324. January 2023 by Firma Nomad Bioscience Posted in General Tagged assay, cell, clinical, drugs, fraunhofer, medical, new, nomad, nomads, pathology, production, research, therapy, vaccines, with

Nomad Bioscience GmbH, Munich, Germany (“NOMAD”) is pleased to announce that the Company has extended its research and development agreement (“Agreement”) with the Fraunhofer Institute of Cell Therapy and Immunology, Leipzig/Halle, Germany (“FRAUNHOFER”) that covers multiple areas of research and […]

NOMAD Bioscience receives patents in Japan and Australia for its antibacterials Salmocins

Posted on 11. October 202211. October 2022 by Firma Nomad Bioscience Posted in General Tagged bacteriocins, biotech, clinical, company, enterica, food, market, medical, nomad, nomads, research, salmocins, salmonella, veterinary, with

NOMAD Bioscience GmbH has announced that the patent offices of Japan and Australia have issued the decisions to grant patents for NOMAD’s patent applications ‘Bacteriocins for the control of Salmonella enterica, JP2019-551665 and AU2018239310.The patents cover NOMAD’s Salmocins, non-antibiotic antibacterial proteins […]

NOMADS UAB, Lithuania Published a Milestone Research Paper Describing its Chimeric Bacteriocins for Control of Multidrug-Resistant Pseudomonas

Posted on 20. April 2022 by Firma Nomad Bioscience Posted in General Tagged aeruginosa, bacteriocins, biosciences, chimera, domain, medical, new, nomad, nomads, paper, pseudomonas, pyocins, rep, research, with

NOMADS UAB, Lithuania, NOMAD Bioscience’s wholly owned subsidiary, announces publication in the Nature group journal Scientific Reports (Š. Paškevičius, V. Dapkutė, A. Misiūnas, M. Balzaris, P. Thommes, A. Sattar, Y. Gleba and A. Ražanskienė, “Chimeric bacteriocin S5-PmnH engineered by domain […]

NOMAD BIOSCIENCE Broadens Its Agreements with Research and Commercial Growers, Spain, to Conduct Pilot Field and Greenhouse Trials Aimed at Industrial Manufacturing of Its Protein Products

Posted on 21. March 202221. March 2022 by Firma Nomad Bioscience Posted in General Tagged cell, clinical, ctaex, del, exploration, extremadura, ibmcp, market, nomad, nomads, olive, origin, smart, thaumatin, with

NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has renewed and extended its development and production agreements with CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURA (“CTAEX”), Badajoz, Spain, TABACOEX cooperative, Rosalejo, and OLIVOS DE BADAJOZ cooperative, Badajoz in […]

NOMAD Bioscience Receives GRAS Regulatory Recognition by FEMA for Its Plant-Made Natural Thaumatin II as a Flavour Modifier/Enhancer

Posted on 17. March 202217. March 2022 by Firma Nomad Bioscience Posted in General Tagged caloric, fda, food, foods, ingredients, market, new, nomad, nomads, ppm, source, sweeteners, thaumatin, thaumatins, with

NOMAD Bioscience GmbH received a formal GRAS recognition letter from the Flavor and Extract Manufacturers Association (FEMA) in response to NOMAD’s GRAS application describing use of plant-expressed Thaumatin II as a flavour modifier/enhancer (FEMA GRAS 5010). FEMA’s expert panel has […]

Prof. Dr. Yuri (Jurijus) Gleba, CEO and majority shareholder of NOMAD Bioscience has supported Ukrainian Army by donating 100 thousand Euro to reinforce the defense against Russian aggression

Posted on 15. March 202215. March 2022 by Firma Nomad Bioscience Posted in General Tagged armed, bioscience, biotechnology, company, defense, entrepreneur, future, german, nomad, other, prof, refugees, russian, thousand, Ukraine

Prof. Dr. Yuri (Jurijus) Gleba, renown scientist and entrepreneur, CEO and major shareholder of Nomad Bioscience GmbH, a German biotechnology company, has donated 100 thousand Euro to the Armed Forces of Ukraine to support the defense against Russian aggression. Prof. […]

NOMAD Bioscience Extends Its GRAS Regulatory Clearance In USA For Plant-Made Natural Thaumatin II As Sweetener, Amendment GRN 910S

Posted on 24. February 202224. February 2022 by Firma Nomad Bioscience Posted in General Tagged 910s, caloric, drug, food, ingredients, market, nomad, nomads, production, protein, source, sugar, sweeteners, thaumatin, thaumatins

NOMAD Bioscience received a formal ‘no questions’ letter from the US Food and Drug Administration (FDA) in response to NOMAD’s GRAS notice amendment GRN 910S describing broader use of plant-produced Thaumatin II as sweetener. Thaumatin II is natural noncaloric high […]

Nomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend and Broaden their Research and Development Agreement

Posted on 4. January 20224. January 2022 by Firma Nomad Bioscience Posted in General Tagged assay, cell, drugs, fraunhofer, influenza, market, nomad, nomads, pathology, production, pseudomonas, research, therapy, vaccines, with

Nomad Bioscience GmbH, Munich, Germany (“NOMAD”) is pleased to announce that the Company has extended and broadened its research and development agreement (“Agreement”) with the Fraunhofer Institute of Cell Therapy and Immunology, Leipzig/Halle, Germany (“FRAUNHOFER”) that covers multiple areas of […]

NOMAD Bioscience Receives Notice of Allowance from USPTO for Its Patent Application ‘Bacteriocins for control of Salmonella enterica’

Posted on 1. September 20212. September 2021 by Firma Nomad Bioscience Posted in General Tagged bacteriocins, clinical, colicins, enterica, medical, nomad, nomads, pseudomonas, registrations, research, salmocins, salmonella, solutions, veterinary, with

NOMAD has announced that the United States’ Patent and Trademark Office (USPTO) has issued the "Notice of Allowance" for the NOMAD’s patent application “Bacteriocins for control of Salmonella enterica”, U.S. Appl. No. 16/577,484. All filed claims of the application necessary […]